Vincamine

Vincamine

SCHEMBL14095103

CC[C@]12CCCN3CCc4c(n(c5ccccc45)[C@](O)(C(=O)OC)C1)[C@@H]32

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 1.00
KCNH2 Q12809 3/20 1.00
CYP2D6 P10635 3/20 1.00
HIF1A Q16665 3/20 1.00
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
KDM4E B2RXH2 2/20 1.00
MAPT P10636 2/20 1.00
GAA P10253 1/20 1.00
CASP6 P55212 1/20 1.00
L3MBTL1 Q9Y468 1/20 1.00
NR1I2 O75469 3/20 0.78
PDE4D Q08499 2/20 0.78
HRH3 Q9Y5N1 2/20 0.78
OPRK1 P41145 1/20 0.78
LMNA P02545 3/20 0.57
CYP1A2 P05177 2/20 0.57
TSHR P16473 2/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Vincamine SCHEMBL147179 1.00 CYP3A4 (1.00) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL3767 1.00 CYP3A4 (1.00) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL30892136 1.00 CYP3A4 (1.00) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL29710919 1.00 CYP3A4 (1.00) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL8970683 1.00 CYP3A4 (1.00) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL8134417 0.99 CYP3A4 (0.98) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL6631357 0.98 CYP3A4 (0.96) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL5712113 0.98 CYP3A4 (0.96) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL6162410 0.97 CYP3A4 (0.95) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL11619815 0.97 CYP3A4 (0.93) CYP3A4KCNH2CYP2D6HIF1AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7410975-B2 Small molecule toll-like receptor (TLR) antagonists COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-08-12 US disclosed
US-7410975-B2 Small molecule toll-like receptor (TLR) antagonists COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-08-12 US disclosed
US-20070232622-A1 Small molecule toll-like receptor (TLR) antagonists COLEY PHARMACEUTICAL GMBH (DE) 2007-10-04 US disclosed
US-20070232622-A1 Small molecule toll-like receptor (TLR) antagonists COLEY PHARMACEUTICAL GMBH (DE) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232622-A1 Small molecule toll-like receptor (TLR) antagonists TLR3, TLR8, TLR7 CYP3A4 2342/4885KCNH2 2466/4885CYP2D6 3808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.